Clinical Trial: Pomalidomide, Elotuzumab and Low-dose Dexamethasone for Relapsed Myeloma - HealthTree for Multiple Myeloma
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial - Transplantation and Cellular Therapy, Official Publication of the ...
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Empliciti (Elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone For Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Combination Therapies - POMALYST® (pomalidomide)
Elotuzumab Plus Pomalidomide and Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma - Hematology Advisor
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials | Haematologica
4138-Multiple myeloma ERd (elotuzumab lenalidomide and dexamethasone) | eviQ
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal
Determining optimal combination regimens for patients with multiple myeloma - ScienceDirect
PDF) Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials | Haematologica
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial - The Lancet Haematology
EMN 29 - Seli-Pom-Dex Vs Elo-Pom-Dex - Multiple Myeloma Clinical Trials
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma
Drug receives priority review for second MM indication | MDedge Hematology and Oncology
Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma - YouTube
Elotuzumab for the treatment of multiple myeloma | Journal of Hematology & Oncology | Full Text
For Relapsed or Refractory Multiple Myeloma, FDA Approves Empliciti Combination
